Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04126200 · OUTCOME

Number of Participants Randomized Across Sub-studies

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Day 1

What was measured

Number of Participants who passed screening and were randomized across sub studies are presented.

Analysis population: All participants who passed screening and were randomized.

Groups in this outcome

All Screened Participants

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Screened Participants208

Reported measurements

Source class 1

Substudy 1

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants9Not reportedNot reportedNot reportedNot reported

Substudy 2

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants25Not reportedNot reportedNot reportedNot reported

Substudy 3

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants106Not reportedNot reportedNot reportedNot reported

Substudy 4

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants4Not reportedNot reportedNot reportedNot reported

Substudy 5

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants30Not reportedNot reportedNot reportedNot reported

Substudy 6

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants20Not reportedNot reportedNot reportedNot reported

Substudy 7

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
All Screened Participants14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
      title
      Substudy 1
    2. measurements
      1. group Id
        OG000
        value
        25
      title
      Substudy 2
    3. measurements
      1. group Id
        OG000
        value
        106
      title
      Substudy 3
    4. measurements
      1. group Id
        OG000
        value
        4
      title
      Substudy 4
    5. measurements
      1. group Id
        OG000
        value
        30
      title
      Substudy 5
    6. measurements
      1. group Id
        OG000
        value
        20
      title
      Substudy 6
    7. measurements
      1. group Id
        OG000
        value
        14
      title
      Substudy 7
denoms
  1. counts
    1. group Id
      OG000
      value
      208
    units
    Participants
description
Number of Participants who passed screening and were randomized across sub studies are presented.
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.
    id
    OG000
    title
    All Screened Participants
param Type
COUNT_OF_PARTICIPANTS
population Description
All participants who passed screening and were randomized.
reporting Status
POSTED
time Frame
Day 1
title
Number of Participants Randomized Across Sub-studies
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice